Ultrashort GnRH Agonist/Antagonist Versus GnRH Antagonist IVF
Launched by SHEBA MEDICAL CENTER · Jun 23, 2014
Trial Information
Current as of May 24, 2025
Unknown status
Keywords
ClinConnect Summary
The ultrashort flare GnRH agonist combined with flexible multidose GnRH antagonist protocol during COH cycle resulted in a significantly higher clinical pregnancy rate in patients with poor embryo quality, with repeated IVF failures and in poor responders. This protocol combines the effect of the microdose flare on endogenous follicle stimulating hormone (FSH) release with the benefit of an immediate luteinizing hormone suppression of the GnRH antagonist.
The basic hypothesis of this approach can also benefit IVF patients with good prognosis without compromising the ability to use gonadotr...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Up to three previous IVF attempts
- Exclusion Criteria:
- • Patients with poor or no response in previous COH for IVF cycles
- • Abnormal ovarian reserve test i.e. anti-mullerian hormone (AMH), Antral follicle test
- • Risk factor for Diminished Ovarian Reserve
About Sheba Medical Center
Sheba Medical Center, located in Israel, is a leading academic medical institution renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, Sheba Medical Center leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies aimed at improving patient outcomes and developing novel therapeutic interventions. The center's collaborative environment fosters partnerships with global research organizations, enhancing its ability to contribute to the scientific community and drive medical advancements across various fields. With a strong focus on patient safety and ethical standards, Sheba Medical Center is dedicated to translating research findings into practical applications that benefit patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ramat Gan, , Israel
Patients applied
Trial Officials
Raoul Orvieto, MD
Principal Investigator
Infertility & IVF Unit, Dept. Obstetrics & Gynecology - Director
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials